Key findings: HER2 positivity, clinical tumour response (RECIST 1.1) and elevated baseline neutrophil count (showing strong linear correlation with apCR, ∗r∗ = 0.97 and p < 0.001) were independent predictors of apCR, with the combined clinical‐haematologic model achieving AUC = 0.766. Here, ERBB2 is linked to neoplasm.